R&D

3

Clinical Study of EarlyTect® Colon Cancer

In a pivotal clinical study, EarlyTect® Colon Cancer Test has been proven to be able to diagnose colorectal cancer with 90.2% sensitivity and 90.2% specificity, and 89.1% sensitivity for early stages (0-II) on 585 subjects at Severance Hospital and Health Promotion Center of Severance Hospital. In addition, the sensitivity is not associated with sex, age, tumor stage and tumor location. EarlyTect® Colon Cancer

  • Sensitivity

    90.2% 플러스 아이콘

  • Specificity

    90.2%
(95% CI 85.8-93.6)

Sensitivity of EarlyTect® CRC Test to clinical stages

  • Stage 0

    100%

    (n=3/3)

  • StageⅠ

    85.5%

    (n=47/55)

  • StageⅡ

    91.4%

    (n=64/70)

  • StageⅢ

    89.6%

    (n=86/96)

  • Stage Ⅳ

    100%

    (n=21/21)
Clinical Study of EarlyTect® Bladder Cancer

In a pilot clinical study, EarlyTect® Bladder Cancer Test has been shown to be able to diagnose bladder cancer with 84.0% sensitivity and 94.0% specificity,
and 74.0% sensitivity for pTa, early stages of bladder cancer, on 574 hematuria subjects at Chungnam National University Hospital, Konyang University Hospital and Daejeon Catholic St. Mary's Hospital.

Clinical Study of EarlyTect® Lung Cancer

In a pivotal clinical study, EarlyTect® Lung Cancer Test has been proven to be able to diagnose lung cancer with 77.8% sensitivity and 92.3% specificity,
and 62.2% sensitivity for early stages (I-II) on 522 subjects at Kyungpook National University Chilgok Hospital. In addition, the sensitivity is not associated with tumor stage, smoking history, or age.